Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Early-stage Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Neratinib
Sponsor: West Cancer Center
Collaborators: Celcuity Inc|Puma Biotechnology, Inc.